The authors have no funding, financial relationships, or conflicts of interest to disclose.
Head and Neck
Prospective testing of mucoepidermoid carcinoma for the MAML2 translocation: Clinical Implications†
Article first published online: 25 JUL 2012
Copyright © 2011 The American Laryngological, Rhinological, and Otological Society, Inc.
Volume 122, Issue 8, pages 1690–1694, August 2012
How to Cite
Chiosea, S. I., Dacic, S., Nikiforova, M. N. and Seethala, R. R. (2012), Prospective testing of mucoepidermoid carcinoma for the MAML2 translocation: Clinical Implications. The Laryngoscope, 122: 1690–1694. doi: 10.1002/lary.22419
- Issue published online: 25 JUL 2012
- Article first published online: 25 JUL 2012
- Manuscript Accepted: 26 SEP 2011
- Manuscript Revised: 21 SEP 2011
- Manuscript Received: 12 JUL 2011
- Mucoepidermoid carcinoma;
- MAML2 translocation;
- prospective testing;
- Level of Evidence: 1b
Mucoepidermoid carcinoma (MEC) with MAML2 translocation is believed to be associated with lower clinical stage, lower histologic grade, and better outcome. We summarized our prospective experience testing MEC for the MAML2 translocation.
Prospective cohort study.
One hundred eighteen head and neck tumors (55 MECs and 63 mimics) were prospectively tested for MAML2 translocation by fluorescence in situ hybridization as part of clinical care during a 36-month period.
MAML2 translocation was identified in 41 of 55 (75%) cases diagnosed as MEC. Translocation status did not correlate significantly with histologic grade, age, gender, tumor site, or T stage.
Routine testing for MAML2 translocation by fluorescence in situ hybridization is feasible and useful in confirming the diagnosis of MEC. The lack of significant correlation with histologic grade or pathologic stage implies that the previously reported prognostic value of the MAML2 translocation may be an artifact of misclassification of MEC as other tumors.